RecruitingNon-Small Cell Lung Cancer
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Eligible age
18+ yrs
Accepts
All genders
Locations
15 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Sponsor: Bristol-Myers Squibb
You may qualify if…
- ✓ Non-squamous NSCLC, not amenable to treatment in curative intent.
- ✓ Documented evidence of EGFR mutation (exon 19 deletion, L858R mutation).
- ✓ Progressive disease on a 3rd-generation (such as osimertinib, furmonertinib, lazertinib,...) EGFR-TKI-based mono- or combination therapy regimen as the most recent line of therapy in an adjuvant, locally advanced, or metastatic treatment setting.
- ✓ Eligible to receive a platinum-based doublet chemotherapy regimen (either cisplatin or carboplatin in combination with pemetrexed).
You may not qualify if…
- ✕ Inadequate organ function and/or bone marrow reserve.
- ✕ Leptomeningeal metastases or spinal cord compression.
- ✕ Poorly controlled systemic medical conditions.
- ✕ Other protocol-defined inclusion/exclusion criteria apply.
Where it's recruiting
California
Irvine · Orange
Colorado
Edwards
Florida
Gainesville · Pembroke Pines
Georgia
Atlanta · Columbus
Illinois
Chicago
Massachusetts
Boston
Missouri
St Louis
Nevada
Reno
New York
Mineola · New York · Rochester
Ohio
Cleveland · Columbus
Oregon
Portland
Pennsylvania
Philadelphia · Pittsburgh
Source: ClinicalTrials.gov · NCT07100080 · last updated 2026-08-25